| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Eagle Pharmaceuticals, Inc. (EGRX) has 0 insiders with recent SEC Form 4 filings, including 4 buys and 16 sells. EGRX is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2019 | Hudson Executive Capital LP49 | Director | Sell | 100 | $60.00 | $6,000.00 | - | |
| Sep 12, 2019 | Hudson Executive Capital LP49 | Director | Sell | 1,312 | $60.06 | $78,798.94 | - | |
| May 10, 2019 | Braunstein Douglas L | Director | Sell | 159,223 | $56.81 | $9,045,972.85 | -8.5% | |
| Apr 1, 2019 | Tarriff Scott | CEO | Sell | 24,975 | $50.15 | $1,252,496.25 | -1.6% | |
| Mar 1, 2019 | Tarriff Scott | CEO | Sell | 24,428 | $51.17 | $1,250,014.68 | -0.8% | |
| Feb 1, 2019 | Tarriff Scott | CEO | Sell | 30,085 | $41.54 | $1,249,831.20 | -1.0% | |
| Jan 3, 2019 | Tarriff Scott | CEO | Sell | 31,569 | $39.49 | $1,246,763.02 | -0.4% | |
| Mar 6, 2018 | Flaum Sander A | Director | Sale+OE | 2,340 | $53.94 | $126,219.60 | -17.1% | |
| Aug 16, 2017 | Meyers Pete A. | Chief Financial Officer | Buy | 350 | $55.45 | $19,406.38 | +100.0% | |
| Aug 9, 2017 | Braunstein Douglas L | Director | Buy | 20,400 | $49.07 | $1,001,086.55 | +0.7% |